摘要
目的:探讨早期苦参素联合拉米夫定(贺浦丁)治疗慢性肝炎YMDD变异的影响。方法:119例患者被随机分为观察组62例,给予贺浦丁100mg/d,口服2年,同时加用苦参素600mg/d,iv,2个月,后600mg/d,口服4个月;对照组57例单用拉米夫定100mg/d,口服2年。结果:疗程结束时(2年),观察HBV-YMDD变异率、HBeAg转换率的变化。两组患者HBeAg血清转换率分别为38.7%和19.2%,HBV-YMDD变异率分别为21.0%和33.3%,观察组疗效明显优于对照组(P<0.01)。结论:苦参素联合拉米夫定能够显著提高HbeAg血清转换率,降低HBV-YMDD变异发生率,建议二者早期联合应用以作为慢性乙型肝炎的一种治疗方案,更深入的研究,待进一步验证。
Objective: To study the influence of oxymatrine combination with lamivudine in treating chronic hepatitis B. Methods: All of 119 patients were randomly divided into 2 groups, 62 patients as a treatment group received 100 mg/d,po,lamivudine combination with 600 mg/d,po,iv,2 mouths, then 600 mg/d,po, 4 mouths;57 patients as a control group was treated only with lamivudine 100 mg/d,po. Results: After completion of therapy (2 years),the mutation rate of YMDD and the negative rate of HbeAg was observed.In the two groups,the negative rate of HbeAg was 38.7%and 19.2%.The mutation rate of YMDD was 21.0%and 33.3%,the efficany of the treatment group was higher than that of control group(P<0.01). Conclusion: oxgmatrine combination with lamivudine can improve the negative rate of HBeAg and reduse the mutation rate of YMDD.
出处
《江苏大学学报（医学版）》
CAS
2005年第2期135-136,138,共3页
Journal of Jiangsu University：Medicine Edition
基金
镇江市科技基金资助项目(SG2001100)
